Universal Ibogaine Inc (IBO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Universal Ibogaine Inc (IBO) has a cash flow conversion efficiency ratio of -0.405x as of April 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-110.36K ≈ $-79.84K USD) by net assets (CA$272.17K ≈ $196.89K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Universal Ibogaine Inc for the company's overall valuation and market capitalisation.
Universal Ibogaine Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Universal Ibogaine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Universal Ibogaine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Universal Ibogaine Inc ranked by their cash flow conversion efficiency. See IBO operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chariot Oil & Gas Limited
LSE:CHAR
|
-0.033x |
|
2cureX AB
ST:2CUREX
|
3.288x |
|
BEACN Wizardry & Magic Inc
V:BECN
|
0.886x |
|
Starbox Group Holdings Ltd. Ordinary Shares
NASDAQ:STBX
|
-0.001x |
|
Handal Resources Bhd
KLSE:7253
|
-0.229x |
|
The Pebble Group PLC
LSE:PEBB
|
0.180x |
|
Sobr Safe Inc
NASDAQ:SOBR
|
-0.982x |
|
Altai Resources Inc.
V:ATI
|
-0.051x |
Annual Cash Flow Conversion Efficiency for Universal Ibogaine Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Universal Ibogaine Inc from 2018 to 2024. View Universal Ibogaine Inc (IBO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-07-31 | CA$991.11K ≈ $716.95K |
CA$-838.61K ≈ $-606.64K |
-0.846x | -35.07% |
| 2023-07-31 | CA$1.75 Million ≈ $1.27 Million |
CA$-1.10 Million ≈ $-793.82K |
-0.626x | +43.00% |
| 2022-07-31 | CA$3.94 Million ≈ $2.85 Million |
CA$-4.33 Million ≈ $-3.13 Million |
-1.099x | -100.15% |
| 2021-07-31 | CA$-4.46K ≈ $-3.22K |
CA$-3.25 Million ≈ $-2.35 Million |
729.129x | +3068.20% |
| 2020-07-31 | CA$94.89K ≈ $68.64K |
CA$-2.33 Million ≈ $-1.69 Million |
-24.565x | -433.93% |
| 2019-07-31 | CA$197.12K ≈ $142.59K |
CA$-906.88K ≈ $-656.02K |
-4.601x | -324.00% |
| 2018-07-31 | CA$295.22K ≈ $213.56K |
CA$-320.34K ≈ $-231.73K |
-1.085x | -- |
About Universal Ibogaine Inc
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.